Members

Marco Antonio Álvarez González (Researcher)

Cristina Álvarez Urturi (PhD Student)

Xavier Bessa Caserras (Researcher)

Felip Bory Ros (Researcher)

Josep Maria Dedeu Cuscó (Researcher)

Lucas Ilzarbe Sánchez (Researcher)

Lucía Márquez Mosquera (Researcher)

M. Francisca Murciano Gonzalo (Technician)

Fausto Riu Pons (PhD Student)

Agustín Seone Urgorri (Researcher)

 

• Main Publications
• Ongoing Research Projects
• Participation in Research Networks

• Group’s Recognitions
• Clinical Trials Signed in 2016
• Theses
• Other

Main Publications

• Abulí A, Castells A, Bujanda L, Lozano JJ, Bessa X, Hernández C, Álvarez-Urturi C, Pellisé M, Esteban-Jurado C, Hijona E, Burón A, Macià F, Grau J, Guayta R, Castellví-Bel S, Andreu M; PROCOLON research group. Genetic Variants Associated with Colorectal Adenoma Susceptibility. PLoS One 2016 14; 11(4): e0153084. IF 3.057. Q1.

• Comas M, Mendivil J, Andreu M, Hernández C, Castells X. Long-Term Prediction of the Demand of Colonoscopies Generated by a Population-Based Colorectal Cancer Screening Program. PLoS One 2016; 12: 11(10): e0164666. IF 3.057 Q1.

• Cubiella J, Carballo F, Portillo I, Cruzado Quevedo J, Salas D, Binefa G, Milà N, Hernández C, Andreu M, Terán Á, Arana-Arri E, Ono A, Valverde MJ, Bujanda L, Hernández V, Morillas JD, Jover R, Castells A. Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy 2016; 48(11): 995-1002. IF 5.634. Q1.

• Xicola RM, Bontu S, Doyle BJ, Rawson J, Garre P, Lee E, de la Hoya M, Bessa X, Clofent J, Bujanda L, Balaguer F, Castellví-Bel S, Alenda C, Jover R, Ruiz-Ponte C, Syngal S, Andreu M, Carracedo A, Castells A, Newcomb PA, Lindor N, Potter JD, Baron JA, Ellis NA, Caldes T, Llor X. Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis 2016; 37(8): 751-8. IF 4.874. Q1.

Ongoing Research Projects

• Early biomarkers in circulating a 4B7 + T cells to predict response to Vedolizumab in inflammatory bowel disease patients

− Takeda Pharmaceutical. IISR-2016-101479

− From 2016 to 2019

− Principal investigator: Márquez Mosquera, Lucía

 

• Optimization of surveillance of adenomatous and serrated polyps. Development of an index of risk of recurrence by environmental, clinical, morphological, histological and molecular factors

− Associación Española Contra el Cáncer (AECC) (PS14152544ANDR)

− From 2015 to 2017

− Principal investigator: Andreu García, Montserrat

 

• Optimization of surveillance of adenomatous and serrated polyps. Development of an index of risk of recurrence by environmental, clinical, morphological, histological and molecular factors

− Fondo de Investigación Sanitaria. ISCIII (PI14/00441)

− From 2015 to 2017

− Principal investigator: Andreu García, Montserrat

 

• Identificación de marcadores epigenéticos de progresión en una cohorte prospectiva de pacientes con cáncer colorrectal (CCR)

− Fondo de Investigación Sanitaria. ISCIII (PI12/01177)

− From 2013 to 2017

− Principal investigator: Bessa Caserras, Xavier

Participation in Research Networks

• COLONPREV: Screening for Colorectal Cancer in Intermediate-Risk Populations: A Multicenter Study Comparing the Occult Blood Detection Test in Feces with Immunological Method and Colonoscopy

− From 2010 to 2020

 

• PROColon Research Group of PDPCCR. National Research group for colorectal cancer population-based screening program

 

• European Polyp Surveillance Trial (EPoS trial) (Horizon 2020)

− From 2015 to 2020

 

• ENEIDA: National Study on Inflamatory Bowel Disease on Genetic and Environmental Determinants

 

• The overall objective of the ENEIDA project is to have an infrastructure and the necessary operational procedures for the continued development of multi-center studies partnerships around the factors involved in the etiology and pathophysiology of inflammatory bowel disease, including genetic and environmental, and epidemiological factors.

Group’s Recognitions

• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca Translacional en Gastroenterologia (2014-2017)

− Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 443)

− Principal investigator: Andreu García, Montserrat

Clinical Trials Signed in 2016

• A phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (ged-0301) for the treatment of subjects with active Crohn’s disease

− Register: GED-0301-002

− Principal investigator: Andreu García, Montserrat

 

• A phase 3, long-term active treatment extension study of mongersen (ged-0301) in subjects with Crohn’s disease

− Register: GED-0301-004

− Principal investigator: Andreu García, Montserrat